In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

The effect of ranolazine-arrhythmia


Ranolazine is an anti-anginal drug that reduces ischemia via inhibition of the late phase of the inward sodium current, which leads to a reduction in intracellular sodium and calcium overload.
Increased intracellular calcium may precipitate electrical instability.

In experimental models, ranolazine reduces pro-arrhythmic substrate and triggers, but the potential anti-arrhythmic actions of ranolazine have yet to be demonstrated in humans.

The MERLIN-TIMI 36 trial randomized 6560 patients with NSTE-ACS to ranolazine or placebo in addition to standard therapy. Continuous ECG (cECG or Holter) recording was performed for the first 7 days after randomization. A prespecified set of arrhythmias were evaluated by a core laboratory blinded to treatment and outcomes. 6351 pts (97%) had cECG recordings evaluable for arrhythmia analysis.

Treatment with ranolazine resulted in significantly lower incidences of arrhythmias. Specifically, fewer patients had an episode of ventricular tachycardia lasting > 8 beats (166 [5.3%] v. 265 [8.3%], p<0.001), supraventricular tachycardia (1413 [44.7%] v. 1752 [55.0%], p<0.001), new-onset atrial fibrillation (55 [1.7%] v.75 [2.4%], p=0.08), or pauses > 3 seconds (97 [3.1%] v. 136 [4.3%], p=0.01).

Among patients admitted with NSTE-ACS, ranolazine reduced the rate of arrhythmias as assessed by cECG monitoring of patients in the first week after admission. These findings support the rationale for future prospective evaluations of ranolazine as an anti-arrhythmic therapy.




Clinical Trial Update II

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.